BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Oct. 1, 2008
View Archived Issues
Nitec Pharma Gets $22M to Fund Lodotra Launch
With a first European approval for its rheumatoid arthritis drug Lodotra imminent, Nitec Pharma AG raised CHF24 million (US$22 million) in a private equity round led by Munich, Germany-based TVM Capital. (BioWorld International)
Read More
Telormedix Gets $19M in Series A Round
Read More
Elucidation of Cancer Growth Yields Potential Drug Targets
Read More
Nextech Closes Oncology Fund with $65M in Hand
Read More
Phynova Focusing on China, Pipeline and Conserving Cash
Read More
Genetically Modified Cotton is Good Neighbor to Other Crops
Read More
NicOx Signs Naproxcinod Agreement with Capsugel
Read More
ExonHit Therapeutics to Provide Genomic Services to French CRO
Read More
FDA Investigating Deaths in Ortho's German Stroke Trial
Read More
Other News To Note
Read More